⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era

Josephine K. Dermawan Ciara M. Kelly Zhidong Gao Shaleigh Smith Bhumika Jadeja Samuel Singer William D. Tap Ping Chi Cristina R. Antonescu

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S5. RFS in primary localized gastric GIST excluding SDH-deficient cases.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dermawan et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db64358752283a https://doi.org/10.1158/1078-0432.27033568

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024
2Supplementary Figure S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024
3Supplementary Figure S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024
4Supplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024
5Supplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024

More related papers

Supplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024
Supplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024
Supplementary Figure S2 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024